文献速递头颈与中枢神经肿瘤

帕博西利联合西妥昔单抗治疗铂类耐药及西妥昔单抗耐药的HPV无关头颈癌:多中心多组2期试验

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-07-24

该多中心多组2期试验评估帕博西利联合西妥昔单抗在铂类耐药(组1)和西妥昔单抗耐药(组2)的HPV无关复发/转移性头颈鳞癌中的活性。组1客观缓解率39%(95%CI 22-59),组2为19%(95%CI 6-38)。最常见3-4级帕博西利相关不良事件为中性粒细胞减少(34%),无治疗相关死亡。

要点

  • 帕博西利联合西妥昔单抗在铂类耐药HPV无关HNSCC中客观缓解率达39%。
  • 西妥昔单抗耐药组客观缓解率为19%,联合方案仍显示一定活性。
  • 常见3-4级不良事件为中性粒细胞减少,发生率34%,无治疗相关死亡。

核心结论

  • 在铂类耐药或西妥昔单抗耐药的HPV无关HNSCC中,帕博西利联合西妥昔单抗显示出有前景的活性。

研究设计与样本

  • 多中心、多组、2期试验,在美国8个大学站点开展,评估帕博西利联合西妥昔单抗在铂类耐药(组1)和西妥昔单抗耐药(组2)HPV无关HNSCC中的活性。
  • 所有患者接受帕博西利口服125 mg/天(第1-21天)和西妥昔单抗静脉给药(首周期第1天400 mg/m2,之后每周250 mg/m2),28天为一周期。

主要发现

  • 组1可评估28例中11例(39%;95%CI 22-59)达到客观缓解。
  • 组2可评估27例中5例(19%;95%CI 6-38)达到客观缓解。
  • 最常见的3-4级帕博西利相关不良事件为中性粒细胞减少,62例中21例(34%)发生;无治疗相关死亡。

临床怎么用

  • 对于铂类耐药或西妥昔单抗耐药的HPV无关复发/转移性HNSCC,帕博西利联合西妥昔单抗可作为一种有前景的治疗选择。
  • 治疗期间需监测中性粒细胞减少等血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most head and neck squamous-cell carcinomas (HNSCCs) are driven by p16INK4A inactivation and cyclin D1 overexpression that results in hyperactivation of cyclin-dependent kinase 4 and 6 (CDK4/6), rather than by the human papillomavirus (HPV). Deregulated cyclin D1 expression also causes resistance to EGFR inhibitors. We previously reported that palbociclib (a selective CDK4/6 inhibitor) given with cetuximab (an EGFR inhibitor) was safe. The aim of this study was to establish the proportion of patients achieving an objective response with palbociclib and cetuximab in recurrent or metastatic HNSCC. METHODS: We did a multicentre, multigroup, phase 2 trial to evaluate the activity of palbociclib and cetuximab in platinum-resistant (group 1) and cetuximab-resistant (group 2) HPV-unrelated HNSCC. The study was done across eight university sites in the USA. Eligibility required measurable disease (according to Response Evaluation Criteria in Solid Tumors, version 1·1 [RECIST 1·1]), Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, age of 18 years or older, and disease progression on platinum but cetuximab-naive (group 1) or disease progression on cetuximab (group 2). All patients received palbociclib orally (125 mg/day, on days 1-21) and intravenous cetuximab (400 mg/m2 on cycle one, day 1, then 250 mg/m2 once per week) in 28-day cycles. The primary endpoint was objective response (complete responses and partial responses per RECIST 1·1). Analyses were done per protocol. This trial was registered with ClinicalTrials.gov, NCT02101034, and is ongoing, but both groups are closed to accrual. FINDINGS: Between Oct 19, 2015, and Nov 7, 2018, 62 patients were enrolled onto the trial: 30 patients were enrolled in group 1 and 32 in group 2. Median follow-up was 5·4 months (IQR 4·4-12·1) for group 1 and 5·5 months (4·3-8·3) for group 2. In group 1, of 28 evaluable patients, an objective response was achieved by 11 (39%; 95% CI 22-59). In group 2, of 27 evaluable patients, an objective response was achieved by five (19%; 6-38) in group 2. The most common grade 3-4 palbociclib-related adverse event was neutropenia (in 21 [34%] of 62 patients). No treatment-related deaths occurred. INTERPRETATION: In patients with platinum-resistant or cetuximab-resistant HPV-unrelated HNSCC, palbociclib and cetuximab results in promising activity outcomes. Further studies of CDK4/6 inhibitors are warranted in HPV-unrelated HNSCC. FUNDING: Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Adkins D, Ley J, Neupane P, et al. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol. 2019. PMID: 31351869. doi:10.1016/S1470-2045(19)30405-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。